Healthcare company Baxter International (NYSE: BAX) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 5% year on year to $2.98 billion. Its non-GAAP profit of $0.58 per share was 11.9% above analysts’ consensus estimates.
Is now the time to buy BAX? Find out in our full research report (it’s free for active Edge members).
Baxter (BAX) Q3 2026 highlights:
- Revenue $2.98 billion vs S&P analysts’ estimates of $2.91 billion (5% year-on-year growth, 2.3% beat)
- Adjusted EPS $0.58 vs S&P analysts’ estimates of $0.52 (11.9% beat)
- Adjusted operating income $432 million vs analyst estimates of $402.9 million (14.5% margin, 7.2% beat)
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $2.10 at the midpoint, a 2.4% increase
- Operating margin 7.6%, up from 6.1% in the same quarter last year
- Constant currency revenue rose 5% year on year (2% in the same quarter last year)
- Market capitalization $12.15 billion
StockStory’s take
Baxter’s third quarter was marked by operational improvements and strategic adjustments, but the market responded negatively despite the company’s results exceeding Wall Street expectations. Management highlighted broad-based growth across core divisions, with Advanced Surgery, Drug Compounding, and Infusion Systems as key contributors. CEO Andrew Hider pointed to improvements in supply chain execution and product quality, noting, “We are seeing more consistent execution and further indicators of improved business performance.” However, the discontinuation of cephalosporin injectables and ongoing supply chain complexities tempered investor sentiment.
Looking forward, management’s raised guidance for the year is underpinned by continued cost discipline, targeted product investments, and a focus on streamlining operations. The company sees further upside from its Baxter GPS efficiency program and ongoing efforts to strengthen the balance sheet. CFO John Rogers cautioned that inflation, tariffs, and the end of certain contract manufacturing agreements could pressure margins in the coming year, but emphasized, “We will be looking to mitigate the impact of those inflationary pressures.” Baxter aims to drive growth through innovation and portfolio simplification while navigating a dynamic macroeconomic environment.
Key insights from management’s remarks
Management attributed the quarter’s performance to steady demand, improved operational execution, and decisive actions to address manufacturing and regulatory challenges while emphasizing ongoing transformation efforts.
- Supply chain improvements: Baxter reduced shipment delays and improved on-time metrics in its Care & Connectivity Solutions division, addressing prior bottlenecks and boosting customer service levels.
- Advanced Surgery demand: The Advanced Surgery segment experienced double-digit growth, benefiting from strong market demand and a competitor’s supply challenges, though management acknowledged these tailwinds may be less pronounced going forward.
- Injectables portfolio shift: The decision to discontinue cephalosporin production at the Round Lake facility will streamline operations and help resolve FDA compliance issues, but comes with a near-term revenue and operating income impact.
- Cost actions and efficiency: The Baxter GPS program drove over 700 improvement initiatives, including cycle time reductions and inventory management enhancements, contributing to better productivity and margin resilience.
- Balance sheet strengthening: Strong free cash flow and a debt tender offer moved the company closer to its net leverage target, positioning Baxter for potential strategic investments and future tuck-in acquisitions.
Drivers of future performance
Baxter’s outlook is shaped by its efforts to offset inflation, manage product transitions, and sustain operational momentum while anticipating margin pressures in 2027.
- Inflation and tariff headwinds: Management expects salary inflation, rising material costs, and potential changes in tariff policy to challenge margins, with plans to offset these through additional cost-savings programs and efficiency gains.
- Portfolio simplification: The exit from cephalosporin injectables and planned product discontinuations in Front Line Care will create top-line and margin headwinds, though management is targeting mitigation through alternative offerings and improved manufacturing focus.
- Capital allocation flexibility: Progress on leverage reduction enhances Baxter’s ability to pursue strategic tuck-in acquisitions and internal investments, but management will maintain a disciplined approach, focusing on long-term returns and market fit.
Catalysts in upcoming quarters
In the coming quarters, the StockStory team will be monitoring (1) Baxter’s execution on supply chain improvements and production transitions, (2) the rate of margin resilience as inflationary and tariff headwinds intensify, and (3) progress on leveraging free cash flow for strategic investments or acquisitions. Additional focus will be on how effectively Baxter navigates product discontinuations and regulatory compliance obligations.
Baxter currently trades at $22.71, down from $25.46 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
High quality stocks for all market conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
